V451 vaccine

V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited.

The vaccine candidate used the University of Queensland's molecular clamp technology[1] and the MF59 adjuvant.

As part of the vaccine's design, researchers added "a fragment of one protein found on the HIV virus"[3] as a "ground-breaking molecular clamp technology".

[4] The development of the vaccine was cancelled on 11 December 2020 during its Phase I trial, after a number of trial participants were found to give false positive test results for HIV antibodies when they did not in fact have HIV.

This is an undesirable outcome as it will interfere with future HIV screening tests for affected participants.